Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Argatroban
Drug ID BADD_D00161
Description Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban.
Indications and Usage Argatroban is indicated for prevention and treatment of thrombosis caused by heparin-induced thrombocytopenia (HIT). It is also indicated for use in patients with, or at risk for, HIT who are undergoing percutaneous coronary intervention.
Marketing Status approved; investigational
ATC Code B01AE03
DrugBank ID DB00278
KEGG ID D00181
MeSH ID C031942
PubChem ID 92722
TTD Drug ID D07UWV
NDC Product Code 42023-182; 0143-9288; 0143-9674; 63323-526; 62227-015; 16729-430; 0143-9559; 70121-1037; 55150-241; 65145-126; 45562-1124; 65219-429; 68083-141; 25021-414; 0143-9377; 0409-1140; 55486-1582; 67457-212; 70333-1191; 76339-118
UNII IY90U61Z3S
Synonyms argatroban | MPQA | (2R,4R)-1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-2-piperidinecarboxylic acid monohydrate | MMTQAP | argatroban monohydrate | argatroban hydrate | Acova | (21R)-argatroban anhydrous | (2R,4R)-1-((2S)-5-((aminoiminomethyl)amino)-1-oxo-2-((((3R)-1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-2-piperidinecarboxylic acid | (21S)-argatroban anhydrous | (2R,4R)-1-((2S)-5-((aminoiminomethyl)amino)-1-oxo-2-((((3S)-1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-2-piperidinecarboxylic acid | (21S)-argatroban | (21R)-argatroban | MD 805 | MD805 | MD-805 | Novastan | argatroban anhydrous | (2R,4R)-1-(5-((aminoiminomethyl)amino)-1-oxo-2-(((1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl)amino)pentyl)-4-methyl-2-piperidinecarboxylic acid | MCI 9038 | MCI-9038
Chemical Information
Molecular Formula C23H36N6O5S
CAS Registry Number 74863-84-6
SMILES CC1CCN(C(C1)C(=O)O)C(=O)C(CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NCC(C3)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Intracardiac thrombus24.01.05.003; 02.11.01.0170.000123%Not Available
Deep vein thrombosis24.01.02.0030.000247%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Haemorrhage24.07.01.0020.000781%Not Available
Pulseless electrical activity02.03.04.0200.000082%Not Available
Vasodilation procedure25.03.01.001--Not Available
Angiopathy24.03.02.007--Not Available
Drug resistance08.06.01.0050.000403%Not Available
Ischaemic stroke24.04.06.010; 17.08.01.0180.000164%Not Available
Disease progression08.01.03.0380.000123%
Renal impairment20.01.03.0100.000082%Not Available
Heparin-induced thrombocytopenia24.01.01.020; 10.02.01.007; 01.08.01.0040.001316%Not Available
Treatment failure08.06.01.0170.000082%Not Available
Acute kidney injury20.01.03.0160.000123%
Amputation stump pain17.02.07.018; 08.01.08.025--Not Available
Hypoxic-ischaemic encephalopathy22.02.02.011; 17.13.02.006; 24.04.06.0210.000082%Not Available
Peripheral artery thrombosis24.01.02.0100.000082%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000123%
Antiphospholipid syndrome24.01.01.029; 18.02.04.002; 10.04.01.009; 01.01.02.0160.000082%Not Available
Haemorrhagic cerebral infarction24.07.04.026; 17.08.01.0500.000082%Not Available
Atrial thrombosis02.11.01.002; 24.01.05.0050.000082%Not Available
Cardiac ventricular thrombosis02.11.01.008; 24.01.05.0060.000082%Not Available
Cerebellar stroke17.08.01.070; 24.04.06.0460.000082%Not Available
The 4th Page    First    Pre   4    Total 4 Pages